RxDoctor Payments Data

Mary Knesevich

Psychiatry · Dallas, TXNPI 1033120811

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (53.0%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 3 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 54.9% of the total. Reporting peaked in 2020 at $1,890 and has fallen 94.3% since, to $108 in 2023.

$3,568in general payments, 2019–2025

Across 6 payments — averaging $594.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$2K
  • Roche TCRC, Inc.$2K
  • Teva Pharmaceuticals USA, Inc.$39
$1,721,869in research payments, 2019–2025

Across 247 payments — averaging $6971.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Neurocrine Biosciences, Inc.$314K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$257K
  • Boehringer Ingelheim$254K
  • Teva Pharmaceuticals USA, Inc.$229K
  • Bioxcel Therapeutics, Inc.$165K
  • Roche TCRC, Inc.$143K
  • plus $359K from 9 others

What the payments were for

  • Consulting fees$1,89053%
  • Travel & lodging$1,14632%
  • Food & beverage$53215%

General payments by program year

20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,568 in reported general payments places this provider in the 80th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas →

Other psychiatry in Dallas

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →